MedPageToday -- Most patients with CD30-positive refractory lymphomas who were treated with a novel antibody–drug conjugate experienced tumor regression -- with some even going into remission -- a phase I study found.
MedPageToday -- Most patients with CD30-positive refractory lymphomas who were treated with a novel antibody–drug conjugate experienced tumor regression -- with some even going into remission -- a phase I study found.
